Patents by Inventor David John Talbutt Vaux

David John Talbutt Vaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090148867
    Abstract: A probe comprises: (1) a target binding site moiety which is attached to a first fluorescent polypeptide; (ii) a mimic moiety which is capable of binding to the target binding site moiety and is attached to a second fluorescent polypeptide; and (iii) a linker which connects the two fluorescent polypeptides and which allows the distance between said fluorescent polypeptides to vary, said fluorescent polypeptides being so as to display fluorescence resonance energy transfer (FRET) between them, wherein the linker comprises one or more of: (1) a sequence capable of being recognised and bound by an immobilized component; (2) a protease cleavage site; (3) a non-analyte binding site; (4) two or more copies of the sequence (SerGly3); or (5) one or more copies of a rod domain from a structural protein.
    Type: Application
    Filed: May 27, 2008
    Publication date: June 11, 2009
    Applicant: Isis Innovation Limited
    Inventors: Mark David Fricker, David John Talbutt Vaux
  • Patent number: 7018839
    Abstract: The acetylcholinesterase 14-mer peptide AEFHRWSSYMVHWK acts alone or in synergism with 2-amyloid to contribute to neuronal degeneration, e.g. in Parkinson's and Alzheimer's diseases, perhaps by exerting calcium channel opening activity. Antibodies and other compounds which inhibit the biological activity are useful for prophylaxis or treatment.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: March 28, 2006
    Assignee: Synaptica Limited
    Inventors: Susan Adele Greenfield, David John Talbutt Vaux
  • Publication number: 20020054870
    Abstract: The acetylcholinesterase 14-mer peptide AEFHRWSSYMVHWK acts alone or in synergism with 2-amyloid to contribute to neuronal degeneration, e.g. in Parkinson's and Alzheimer's diseases, perhaps by exerting calcium channel opening activity. Antibodies and other compounds which inhibit the biological activity are useful for prophylaxis or treatment.
    Type: Application
    Filed: October 23, 1998
    Publication date: May 9, 2002
    Applicant: SYNAPTICA LIMITED
    Inventors: SUSAN ADELE GREENFIELD, DAVID JOHN TALBUTT VAUX